Skip to main content
SpringerLink
Log in

Organotypic Models in Drug Development

  • Book
  • © 2021

Overview

Editors:
  1. Monika Schäfer-Korting

    1. Institut für Pharmazie, FU Berlin, Berlin, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Silvya Stuchi Maria-Engler

    1. School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Robert Landsiedel

    1. BASF SE, Experimental Toxicology und Ecology, Ludwigshafen am Rhein, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Maximizes the understanding of drug effects in human
  • Broadens insights into drop-outs in drug development
  • Maximizes reader insights into innovative techniques in drug testing based on human derived material

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 265)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (12 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. General Topics – Quality Assurance and Predictability

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh

      • Susanne N. Kolle, Robert Landsiedel
      Pages 3-27

    3. How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development

      • Monika Schäfer-Korting, Christian Zoschke
      Pages 29-56

    4. Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development

      • Helena Kandarova, Patrick J. Hayden
      Pages 57-71

  3. Models For Drug Research

    1. Front Matter

      Pages 73-73
      Download chapter PDF

    2. In Vitro Models of the Blood-Brain Barrier

      • Winfried Neuhaus
      Pages 75-110

    3. Neural In Vitro Models for Studying Substances Acting on the Central Nervous System

      • Ellen Fritsche, Julia Tigges, Julia Hartmann, Julia Kapr, Melania Maria Serafini, Barbara Viviani
      Pages 111-141

    4. Engineered Heart Muscle Models in Phenotypic Drug Screens

      • Wolfram-Hubertus Zimmermann
      Pages 143-156

    5. Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection

      • Patrick Carius, Justus C. Horstmann, Cristiane de Souza Carvalho-Wodarz, Claus-Michael Lehr
      Pages 157-186

    6. Skin Disease Models In Vitro and Inflammatory Mechanisms: Predictability for Drug Development

      • Hans Christian Hennies, Yves Poumay
      Pages 187-218

    7. Immunocompetent Human Intestinal Models in Preclinical Drug Development

      • Günther Weindl
      Pages 219-233

    8. Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling

      • Zhong Li, Shiqi Xiang, Eileen N. Li, Madalyn R. Fritch, Peter G. Alexander, Hang Lin et al.
      Pages 235-268

    9. Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development

      • Érica Aparecida de Oliveira, Colin R. Goding, Silvya Stuchi Maria-Engler
      Pages 269-301

    10. The CAM Assay as an Alternative In Vivo Model for Drug Testing

      • Regine Schneider-Stock, Domenico Ribatti
      Pages 303-323
Back to top

Keywords

About this book

This book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide. 

Editors and Affiliations

  • Institut für Pharmazie, FU Berlin, Berlin, Germany

    Monika Schäfer-Korting

  • School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

    Silvya Stuchi Maria-Engler

  • BASF SE, Experimental Toxicology und Ecology, Ludwigshafen am Rhein, Germany

    Robert Landsiedel

Bibliographic Information

  • Book Title: Organotypic Models in Drug Development

  • Editors: Monika Schäfer-Korting, Silvya Stuchi Maria-Engler, Robert Landsiedel

  • Series Title: Handbook of Experimental Pharmacology

  • DOI: https://doi.org/10.1007/978-3-030-70063-8

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Nature Switzerland AG 2021

  • Hardcover ISBN: 978-3-030-70062-1Published: 26 March 2021

  • Softcover ISBN: 978-3-030-70065-2Published: 29 March 2022

  • eBook ISBN: 978-3-030-70063-8Published: 25 March 2021

  • Series ISSN: 0171-2004

  • Series E-ISSN: 1865-0325

  • Edition Number: 1

  • Number of Pages: VIII, 323

  • Number of Illustrations: 33 b/w illustrations, 37 illustrations in colour

  • Topics: Pharmacology/Toxicology, Gene Therapy, Pathology

Publish with us

Policies and ethics

Back to top

Search

Navigation